Next Investors logo grey

The start-up scene is taking shape

Published 18-DEC-2015 11:52 A.M.


4 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

The start-up scene is thriving in Australia. While we are not quite at Silicon Valley or Israeli-innovation levels, it seems the world is taking notice, particularly after Atlassian’s IPO became the biggest of any Australian company listing on a public sharemarket.

Atlassian’s record-breaking valuation was AU$6.1BN after being substantially oversubscribed.

It will have many Australian start-ups looking to follow suit.

One start-up that is making waves is Shoes of Prey, the start-up that pioneered on-demand customised fashion footwear globally.

Shoes of Prey recently announced a US$15.5 million Series B capital raising.

Shoes of Prey is changing the way people access fashion, by giving them the power to design their own shoes online and choose from trillions of combinations of style, heel height, material, colour, size and width. Women across the world have designed more than five million shoes on Shoes of Prey since the company was founded in 2009.

Earlier this year the company rolled out physical design studios in six Nordstrom stores across the US. The brand is now also available on, which establishes an important new sales channel for Shoes of Prey.

Shoes of Prey will use the funding to continue growing its omnichannel retail presence in the US. The funding will also increase production capacity in the company’s dedicated factory in China to cater to increased consumer demand in the US and globally for customised products, and to accelerate future expansion into new products, starting with women’s handbags.

Following the relocation of the brand’s headquarters from Sydney to Los Angeles earlier this year, Shoes of Prey is also aggressively hiring to support its rapid growth, currently at 120 per cent year on year.

Jodie Fox, Co-founder of Shoes of Prey, said “Our mission is to empower customers to shop without compromise. Our customers know exactly what they want in shoes, regardless of whether it’s in stock or in season, and we’re proud to deliver a solution that caters to that otherwise unserved need.

“The Nordstrom investment follows a number of acquisitions of, and investments in, innovative retail companies in recent years, and shows the company’s continued commitment to offering customers an unparalleled shopping experience. It was an easy decision for us to welcome Nordstrom, the leaders in shoe retail and customer service,” Fox said.

Another Australian business who could do big things is Omniblend Innovation, who has recently entered into a binding agreement with EVE Investments for Eve to acquire a 40% stake in the company.

EVE will publicly list Omniblend Innovation within two years.

The company is finalising a production ready patented food-grade pre-meal drink named GlucoSmoothTM for managing type 2 diabetes.

The product is expected to be on pharmacy shelves early in 2016, with a distribution deal already in place to put the product on 6000 Australian shelves.

A new report predicts diabetes will be a $55.3BN global market by 2017, with over 387 million people managing the disease. In 2012 alone the antidiabetic medicines industry generated $35.6BN.

While Omniblend’s primary markets will be in Australia, New Zealand, China and the US, that’s a big enough slice of the pie to make an impact.

“With a huge global market of people living with T2D and pre-diabetes, Omniblend Innovation’s lead product, GlucoSmoothTM fills a niche gap, enabling people to ease the burden of living with this chronic disease through a clinically proven natural food grade product. GlucoSmoothTM enables people to choose from a significantly enhanced range of foods without risking high spikes in their blood glucose levels. The blood sugar spikes contribute to serious long term health complications. With support from EVE Investments, we are able to accelerate our growth and put GlucoSmoothTM on the shelves of pharmacies across Australia and New Zealand early next year.”

Add companies such as the IoT Group making their mark in wearables and home technology, MGC Pharmaceuticals who could capitalise on the growing positive sentiment towards medical marijuana, XTEK who are evolving the military drone and armour space, Newzulu affecting the media landscape and Activistic (who are making donations more palatable by actually giving more back to a charity than is currently being taken by organisers and payment processors) and we have an exciting and emerging group of start-ups making their mark.

The start-up scene is thriving across the country, with Sydney leading the way and the few start-ups here are just a drop in the ocean.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.